Sign in
CompletedNo phase

A Registry for Participants With Chronic Hypoparathyroidism

Key facts

Who runs it
Takeda
Where
Albany, Arlington Heights, Aurora, Austin, Baltimore, Birmingham, Boston, Brooklyn, Charlotte, Chicago, Cleveland, Columbia, Columbus, Dallas, East Providence, El Paso, Evanston, Fort Worth, Greenville, Honolulu, Indiana, Indianapolis, Las Vegas, Los Angeles, Madison, Marrero, Maywood, Minneapolis, New Brunswick, New Haven, New York, Omaha, Philadelphia, Pittsburgh, Port Charlotte, Reno, Rochester, San Jose, Sarasota, Smithtown, South Burlington, Staten Island, Syracuse, and Tucson, United StatesSee the 53 sitesAlso in 10 other countries, 46 sites
Trial code
Status
Completed
People taking part
1,339 people enrolled
Started
30 Jul 2013
Ended
30 Jun 2026
Type of study
Observational, 2 groups
Record updated
14 July 2026

Who can take part

Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Participants diagnosed with chronic hypoparathyroidism, that is, hypoparathyroidism with a duration of longer than 6 months, including:; Adult participants (greater than or equal to [>=] 18 years of age) who are receiving for chronic hypoparathyroidism any of the following options: standard therapy, standard therapy plus rhPTH(1-84), or rhPTH(1-84) therapy alone; Pediatric participants (less than [<] 18 years of age) who are receiving for chronic hypoparathyroidism any of the following options: standard therapy, standard therapy plus rhPTH(1-84), or rhPTH(1-84) therapy alone

Who cannot take part

  • Participants using rhPTH(1-34) or who used rhPTH(1-34) for more than 2 years are excluded. Participants who had been treated with rhPTH(1-34) within 3 months of enrollment are also excluded as are participants currently using rhPTH(1-34); FOR US SITES ONLY: Participants treated with rhPTH(1-84) prior to the US recall may use rhPTH(1-34) only while rhPTH(1-84) is unavailable due to the recall
  • History of hypoparathyroidism resulting from impaired responsiveness to PTH (pseudohypoparathyroidism)
  • Participants or legally acceptable representatives unable to provide informed consent
  • Participants currently enrolled in an interventional clinical study (whether or not the study is related to hypoparathyroidism); note that this does not include participants enrolled in other observational registries

Where in United States

Also in 10 other countries, 46 sites

  • Albany Med Endocrine SpecialistsAlbany, United States
  • Suburban Endocrinology & DiabetesArlington Heights, United States
  • University of Colorado HospitalAurora, United States
  • Texas Diabetes and Endocrinology, P.AAustin, United States
  • MedStar Union Memorial HospitalBaltimore, United States
  • MODEL Clinical researchBaltimore, United States
  • University of Alabama at BirminghamBirmingham, United States
  • Boston Medical CenterBoston, United States
  • Brigham and Women's HospitalBoston, United States
  • Harvard Medical SchoolBoston, United States
  • Massachusetts General HospitalBoston, United States
  • Brokhin Medical PCBrooklyn, United States
  • Mecklenburg Medical GroupCharlotte, United States
  • University of Chicago Medical CenterChicago, United States
  • Cleveland ClinicCleveland, United States
  • University of MissouriColumbia, United States
  • University of South CarolinaColumbia, United States
  • Ohio Health Research InstituteColumbus, United States
  • Ohio State University Wexner Medical CenterColumbus, United States
  • Thyroid, Endocrinology, and DiabetesDallas, United States
  • Hallett Center for Diabetes and EndocrinologyEast Providence, United States
  • Academy of Diabetes, Thyroid and EndocrineEl Paso, United States
  • Northshore University Health SystemEvanston, United States
  • Diabetes and Thyroid Center of Fort Worth, PLLCFort Worth, United States
  • Physicians East, PAGreenville, United States
  • East-West Medical Research InstituteHonolulu, United States
  • Endocrinology Associates of ArmstrongIndiana, United States
  • Indiana University HospitalIndianapolis, United States
  • Palm Research Center IncLas Vegas, United States
  • Cedars-Sinai Medical CenterLos Angeles, United States
  • Children's Hospital Los AngelesLos Angeles, United States
  • University of WisconsinMadison, United States
  • Tilak Mallik, MD F.A.C.E., LCCMarrero, United States
  • Loyola University Medical CenterMaywood, United States
  • University of MinnesotaMinneapolis, United States
  • Rutgers, Robert Wood Johnson Medical SchoolNew Brunswick, United States
  • Yale UniversityNew Haven, United States
  • Columbia University Medical CenterNew York, United States
  • Gerald Friedman Diabetes InstituteNew York, United States
  • Diabetes & Endocrine Associates, Methodist Physicians Clinic Diabetes and Endocrine SpecialistsOmaha, United States
  • The Children's Hospital Of PhiladelphiaPhiladelphia, United States
  • Thomas Jefferson UniversityPhiladelphia, United States
  • Alleghany General HospitalPittsburgh, United States
  • Hanson Clinical Research CenterPort Charlotte, United States
  • Northern Nevada EndocrinologyReno, United States
  • Mayo Clinic - RochesterRochester, United States
  • Dr. Joselito CabaccanSan Jose, United States
  • Thyroid & Endocrine Center of FloridaSarasota, United States
  • Endocrine Associates of Long Island, P.C.Smithtown, United States
  • University of VermontSouth Burlington, United States
  • University Physicians Group Research DivisionStaten Island, United States
  • State University of New York Upstate Medical UniversitySyracuse, United States
  • University of Arizona Medical CenterTucson, United States

About the trial

What the trial wants to find out

The main aim of this study is to find out the long-term safety and effectiveness profile of recombinant human parathyroid hormone (1-84) (rhPTH[1-84]) treatment in participants with chronic hypoparathyroidism under conditions of routine clinical practice.

Read full original descriptionShow less

Participants will be treated according to their clinic's standard practice determined by the treating doctors. Each participant will fill out a study questionnaire during a routine doctor visit.

The 2 groups in the trial

  • Natpar(a)

    Participants receiving parathyroid hormone (rhPTH(1-84) (Natpar\[a\]) for treatment of chronic hypoparathyroidism as per standard clinical practice will be enrolled and evaluated during the study period.

  • Conventional Therapy

    Participants receiving conventional therapy/standard of care (including calcium supplements, active vitamin D, vitamin D) for treatment of chronic hypoparathyroidism as per standard clinical practice will be enrolled and evaluated during the study period.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Registry for Patients With Chronic Hypoparathyroidism
Publications
Record updated
14 July 2026